drugset / Trial / NCT05508659

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

NCT05508659

Phase 1/2 Unknown 128 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Study will be conducted with 2 stages.

Timeline

Start
2022-09-20
Primary completion
2024-09-20
Completion
2025-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Duvelisib Small molecule Oral
Subject Enlonstobart Monoclonal antibody 240 mg Intravenous

Indications